Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study
Masri A, Aras M, Falk R, Grogan M, Jacoby D, Maurer M, Shah S, Witteles R, Wong P, Ji A, Du J, Siddhanti S, Sinha U, Fox J, Judge D. Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study. Journal Of Cardiac Failure 2024, 30: 221. DOI: 10.1016/j.cardfail.2023.10.251.Peer-Reviewed Original ResearchOpen-label extensionATTR-CMAmyloid cardiomyopathyPhase 3 randomized clinical trialMedian NT-proBNP levelOpen-label extension studyNYHA class IIMedian follow-upNT-proBNP levelsPhase 2 studyPhase 2 trialTransthyretin amyloid cardiomyopathyNT-pro-BNPOpen-label studyLong-term treatmentLong-term safetyEx vivo assaysDouble-blindPlacebo-controlledNT-proAdverse eventsFollow-upClinical trialsConcurrent illnessDay 1